LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Cogent Biosciences Inc

Fechado

12.82 1.75

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.55

Máximo

12.97

Indicadores-chave

By Trading Economics

Rendimento

-1.5M

-74M

Margem de lucro

-1,582.642

Funcionários

205

EBITDA

1.7M

-72M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+64.98% upside

Dividendos

By Dow Jones

Próximos Ganhos

10 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

7.7M

1.7B

Abertura anterior

11.07

Fecho anterior

12.82

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de set. de 2025, 23:37 UTC

Ações em Alta

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 de set. de 2025, 20:41 UTC

Ganhos

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 de set. de 2025, 20:30 UTC

Ganhos

GameStop 2Q Sales, Profit Rise

9 de set. de 2025, 23:19 UTC

Conversa de Mercado

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 de set. de 2025, 21:35 UTC

Ganhos

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 de set. de 2025, 21:32 UTC

Ganhos

Oracle's Backlog Swells With Big Customer Deals -- Update

9 de set. de 2025, 21:02 UTC

Aquisições, Fusões, Aquisições de Empresas

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de set. de 2025, 20:33 UTC

Ganhos

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 de set. de 2025, 20:26 UTC

Ganhos

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 de set. de 2025, 20:23 UTC

Ganhos

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 de set. de 2025, 20:12 UTC

Ganhos

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 de set. de 2025, 20:10 UTC

Ganhos

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 de set. de 2025, 20:10 UTC

Ganhos

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 de set. de 2025, 20:09 UTC

Ganhos

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 de set. de 2025, 20:09 UTC

Ganhos

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 de set. de 2025, 20:08 UTC

Ganhos

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 de set. de 2025, 20:08 UTC

Ganhos

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 de set. de 2025, 20:08 UTC

Ganhos

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 de set. de 2025, 20:08 UTC

Ganhos

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 de set. de 2025, 20:07 UTC

Ganhos

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 de set. de 2025, 20:06 UTC

Ganhos

Oracle 1Q Software Revenue $5.72B >ORCL

9 de set. de 2025, 20:06 UTC

Ganhos

Synopsys 3Q Adj EPS $3.39 >SNPS

9 de set. de 2025, 20:06 UTC

Ganhos

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Rev $14.93B >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q EPS $1.01 >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Synopsys 3Q EPS $1.50 >SNPS

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Services Revenue $1.35B >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Adj EPS $1.47 >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Hardware Revenue $670M >ORCL

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

64.98% parte superior

Previsão para 12 meses

Média 20.92 USD  64.98%

Máximo 30 USD

Mínimo 10 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

10

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.88 / 5.87Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Strong Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
help-icon Live chat